DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 4 John Sharretts - 3 Wegovy - 3 Eli Lilly's - 2 Lilly - 2 Ozempic - 1 Zepbound - 1 CNN — Wegovy’s - 1
Top related locs:
U.S United States Oslo Norway Danish Branchburg , New Jersey Indianapolis New York
Top related orgs:
Drug Administration - 3 Novo Nordisk - 3 Drug - 3 FDA - 3 Diabetes - 2 FDA's Center - 2 Research - 2 U.S - 2

Search resuls for: "John Sharretts"


4 mentions found


☆ Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage
  + stars: | 2024-03-08 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. The approval also demonstrates that weight loss drugs have significant health benefits beyond shedding unwanted pounds and regulating blood sugar. The FDA said Wegovy patients should use Wegovy in addition to a reduced calorie diet and increased physical activity. Novo Nordisk expects to receive a similar Wegovy approval in the EU this year. The study tested Wegovy in roughly 17,500 people with obesity and heart disease but who did not have diabetes.
Persons: John Sharretts, Ozempic, Wegovy, Eli Lilly, Zepbound Organizations: Drug Administration, Novo Nordisk, Diabetes, FDA's Center, Drug, Research, FDA, Nordisk Locations: Oslo, Norway, Danish, U.S
☆ Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update
  + stars: | 2024-03-08 | by ( Meg Tirrell | ) edition.cnn.com   time to read: +4 min
The label expansion may improve insurance coverage for Wegovy, which costs more than $1,300 per month out of pocket before any discounts. Many insurers, including Medicare, don’t cover drugs for weight loss, leaving patients scrambling to afford them. “This patient population has a higher risk of cardiovascular death, heart attack and stroke,” he added. More studies need to be done to show whether there are heart benefits for people who haven’t had a cardiac event. Wegovy continues to be in shortage, along with other GLP-1 medicines, as drugmakers struggle to keep up with demand.
Persons: CNN — Wegovy’s, –, Dr, Harlan Krumholz, hasn’t, Eli Lilly, Wegovy, John Sharretts, haven’t, it’s, Sanjay Gupta, Jody Dushay, Beth, Dushay, Novo, Doug Langa, ” Organizations: CNN, US Food and Drug Administration, Yale University, Yale New Haven Hospital, Novo Nordisk, Diabetes, ”, CNN Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Novo Nordisk’s, North America Operations
☆ US approves Lilly weight-loss drug, will compete with Novo's Wegovy
  + stars: | 2023-11-08 | by ( Patrick Wingrove Bhanvi Satija | Patrick Wingrove | Bhanvi Satija | ) www.reuters.com   time to read: +4 min
The FDA approved tirzepatide for weight loss under the brand name Zepbound. It has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending. Zepbound will be available in the U.S. by the end of the year at a list price of $1,059.87 a month, according to Lilly. That compares with a list of $1,349 per-package for Novo Nordisk's (NOVOb.CO) wildly popular weight-loss drug Wegovy. After Wednesday's FDA approval, Lilly can now promote the drug for weight loss.
Persons: Eli Lilly, Mike Segar, Eli Lilly's, ” John Sharretts, Lilly, Morningstar, Damien Conover, Conover, drugmaker, Robert Kushner, Mounjaro, Patrick Wingrove, Leroy Leo, Bhanvi, Shinjini Ganguli, Bill Berkrot Organizations: Company, REUTERS, U.S . Food, Drug Administration, U.S, FDA, FDA’s Center, Drug, Research, Novo Nordisk's, Reuters, Northwestern University Feinberg School of Medicine, Thomson Locations: Branchburg , New Jersey, U.S, Indianapolis, United States, New York, Bengaluru
☆ FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
  + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +6 min
George Frey | ReutersThe Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The FDA said the approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average. The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Preliminary data is already available: A recent late-stage trial found that Novo Nordisk's weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%.
Persons: George Frey, Eli Lilly, John Sharretts, Eli Lilly's, Wegovy, Lilly, Mike Mason, Eli Lilly Diabetes Organizations: Novo Nordisk, Pharmacy, Reuters, Food, Drug Administration, U.S, FDA's Center, Drug, FDA, Obesity Locations: Provo , Utah, U.S, United States
0 next >>
Total: 4